— Published Date: 5/14/2025
Value Proposition: Robust and reliable biomarker to accurately predict patient response to PARP inhibitors and platinum chemotherapy for high grade serous ovarian cancer.
Technology Description
Researchers at Washington University in St. Louis have developed an automat…
— Published Date: 5/14/2025
Value proposition: Self-sustaining chimeric macrophages as a novel approach to target amyloid plaques resulting in improved efficacy and survival in patients.
Technology Description
Researchers from Washington University in St. Louis have engineered macrophages to expre…
— Published Date: 12/21/24
Value proposition: A cost-effective, drug-based therapy targeting the endothelin B receptor (ETBR) to promote peripheral nerve regeneration, offering improved recovery and compatibility with existing treatments.
Technology Description
Researchers at Washington University…
— Published Date: 12/24/2024
Value proposition: An advanced CAR-T cell therapy engineered to reduce T cell exhaustion, enhancing durability and effectiveness in cancer treatment by overcoming one of the leading causes of long-term treatment failure.
Technology Description
Researchers at Washington…
— Published Date: 5/13/2025
Value Proposition: A novel approach to repurposing FDA-approved anti-epileptic drugs to treat brain and nerve tumors associated with neurofibromatosis type I, offering a faster, cost-effective pathway to address an urgent unmet medical need.
Technology Description
Neuro…
| Name | # Summaries | Author |
|---|---|---|
| 15 | ||
| 13 | ||
| 15 | ||
| 26 | ||
| 14 | ||
| 14 |
Creating...
